- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00520897
Integrase Inhibitor (MK-0518) Viral Decay
June 4, 2012 updated by: Canadian Immunodeficiency Research Collaborative
Effect of Integrase Inhibitor (MK-0518) on Decay of Low Level Viral Replication in HIV Reservoirs in Infected Individuals Who Initiated Conventional Antiretroviral Therapy During the Chronic Phase of Infection
The eradication of HIV by antiretroviral therapy has thus far been elusive.
It has been consistently demonstrated that a pool of latently infected, resting CD4+ T cells persists in the majority of HIV-infected individuals receiving antiretroviral therapy in whom plasma viremia has been successfully suppressed for prolonged periods of time; this pool has emerged as the major obstacle in achieving the eradication of HIV.
We believe that MK-0518 can further the decay and suppression of HIV-1 in patients who have been virologically suppressed for a prolonged period of time on effective cART (≥ 4 years).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The trial is a prospective, double-blind, randomized, placebo-controlled study with two phases: phase I to 48 weeks and phase II to 96 weeks with the primary analysis at 48 weeks.
HIV-infected individuals who are taking their first standard cART regimen for at least four years with complete viral suppression.
Upon enrollment, he/she will be randomized to one of two arms: the MK-0518 arm or the control arm.
As each participant reaches week 48, he/she will be unblinded and those in the MK-0518 arm will continue taking MK-0518.
Based on the results of an interim analysis, the control arm will be rolled over to receive MK-0518 for 48 weeks.
After the screening, baseline visits and week 4 safety visit, follow-up visits will occur every 8 weeks for both arms.
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5B 1L6
- Maple Leaf Medical Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participant must be HIV-1 infected
- Participant must be 18 years old
- Participant must be taking first standard cART with 2-3 NRTIs and 1-2 PIs or an NNRTI for at least four years (first cART regimen may include changes due to toxicity but not due to virologic failure).
- Participant must have a VL < 50 copies/ml (using the standard available methods of detection) during the entire time on standard cART except for initial fall of VL and a maximum of two non-consecutive blips of < 100 copies/ml that the study investigator deems to be not clinically significant
- Female participant must agree to use two methods of birth control or abstinence during the period of the study
- Participant has to have signed full informed consent
Exclusion Criteria:
- Participant who would have difficulty participating in a trial due to non-adherence or substance abuse
- Participant who has taken mono or dual antiretroviral therapy in the past
- Participant who has had a VL > 50 copies/ml on any antiretroviral regimen
Participant with any of the following abnormal laboratory test results in screening:
- Hemoglobin < 100 g/L
- Neutrophil count < 750 cells/L
- Platelet count < 50,000 cells/L
- AST or ALT > 5X the upper limit of normal
- Creatinine > 250 mol/L
- Participant with a malignancy
- Participant with other significant underlying disease (non-HIV) that might impinge upon disease progression or death
- Participant with an active AIDS-defining illness in the past six months
- Participant who is pregnant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MK0518 + cART
Raltegravir + standard of care combined antiretroviral therapy
|
400mg BID; 48 weeks
pack of cells as per protocol
gut samples as per protocol
|
Placebo Comparator: Placebo + cART
Placebo + standard of care combined antiretroviral therapy
|
pack of cells as per protocol
gut samples as per protocol
400mg QD
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change of proviral HIV-1 DNA in total CD4+ T cells from baseline to week 48
Time Frame: 48 weeks
|
evaluate the change of proviral HIV-1 DNA in total CD4+ T cells from baseline to week 48 in participants randomized to the raltegravir arm (400mg raltegravir) for 48 weeks in addition to their current standard combination antiretroviral regimen versus the control arm, who remained on their current standard combination antiretroviral regimen.
|
48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
evaluated the effect of raltegravir intensification on blood CD4+ T cell populations
Time Frame: 48 & 96 weeks
|
evaluated the effect of raltegravir intensification on blood CD4+ T cell populations.
In addition, after treatment-intensification in both groups at week 48, a post-hoc follow-up of all participants was conducted up to week 96 to examine if raltegravir intensification had any long-term effects on proviral HIV DNA and CD4+ T cell populations in the blood and gut.
|
48 & 96 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Mona Loutfy, MD, Women's College Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2007
Primary Completion (Actual)
February 1, 2009
Study Completion (Actual)
November 1, 2011
Study Registration Dates
First Submitted
August 24, 2007
First Submitted That Met QC Criteria
August 24, 2007
First Posted (Estimate)
August 27, 2007
Study Record Updates
Last Update Posted (Estimate)
June 5, 2012
Last Update Submitted That Met QC Criteria
June 4, 2012
Last Verified
June 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- HIV Integrase Inhibitors
- Integrase Inhibitors
- Raltegravir Potassium
Other Study ID Numbers
- 038-00
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Raltegravir (MK0518)
-
Merck Sharp & Dohme LLCCompletedHIV Infections | Acquired Immunodeficiency Syndrome
-
Merck Sharp & Dohme LLCTerminated
-
Merck Sharp & Dohme LLCApproved for marketing
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedHIV Infections | Acquired Immunodeficiency Syndrome
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIV InfectionsUnited States, Puerto Rico, South Africa, Argentina, Brazil, Botswana
-
Massachusetts General HospitalMerck Sharp & Dohme LLCCompletedHIV | Neurotoxicity | HIV-associated Neurocognitive DisorderUnited States
-
ViiV HealthcareCompletedInfection, Human Immunodeficiency VirusUnited States